Alpha-fetoprotein and
Carcinoma, Hepatocellular
/ blood
Female
Fluorodeoxyglucose F18
Humans
Liver Neoplasms
/ blood
Liver Transplantation
Male
Middle Aged
Neoplasm Recurrence, Local
/ blood
Neoplastic Cells, Circulating
/ pathology
Portal Vein
/ pathology
Positron-Emission Tomography
Predictive Value of Tests
Preoperative Period
Radiopharmaceuticals
Risk Factors
Survival Rate
Tumor Burden
alpha-Fetoproteins
/ metabolism
Alpha-fetoprotein
Hepatocellular carcinoma
Liver transplantation
Portal vein tumor thrombosis
Standard uptake value
Journal
Hepatobiliary & pancreatic diseases international : HBPD INT
ISSN: 1499-3872
Titre abrégé: Hepatobiliary Pancreat Dis Int
Pays: Singapore
ID NLM: 101151457
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
02
06
2019
accepted:
23
03
2020
pubmed:
19
4
2020
medline:
7
4
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
Portal vein tumor thrombosis (PVTT) is regarded as a contraindication for liver transplantation (LT) in hepatocellular carcinoma (HCC). However, some of these patients may have a favorable prognosis after LT. In this study, we evaluated the biological behavior of HCC with PVTT using tumor biomarker (alpha-fetoprotein, AFP) and Seventy-five HCC-PVTT liver recipients transplanted during February 2016 and June 2018 were analyzed. Different pre-transplant prognostic factors were identified by univariate and multivariate analyses. PVTT status was identified following Vp classification (Vp1-Vp4). Three-year recurrence-free survival and overall survival rates were 40% and 65.4% in Vp2-Vp3 PVTT patients, 21.4% and 30.6% in Vp4 PVTT patients (P < 0.05). Total tumor diameter >8 cm, pre-transplant AFP level >1000 ng/mL and intrahepatic tumor maximal standard uptake value (SUVmax-tumor >5) were independent risk factors for HCC recurrence and overall survival after LT in Vp2-3 PVTT patients. Low risk patients were defined as total tumor diameter ≤8 cm; or if total tumor diameter more than 8 cm, with both pre-transplant AFP level less than 1000 ng/mL and intrahepatic tumor SUVmax less than 5, simultaneously. Twenty-two Vp2-3 PVTT HCC patients (46.8%) were identified as low risk patients, and their 3-year recurrence-free and overall survival rates were 67.6% and 95.2%, respectively. Patients with segmental or lobar PVTT and biologically favorable tumors defined by AFP and
Sections du résumé
BACKGROUND
BACKGROUND
Portal vein tumor thrombosis (PVTT) is regarded as a contraindication for liver transplantation (LT) in hepatocellular carcinoma (HCC). However, some of these patients may have a favorable prognosis after LT. In this study, we evaluated the biological behavior of HCC with PVTT using tumor biomarker (alpha-fetoprotein, AFP) and
METHODS
METHODS
Seventy-five HCC-PVTT liver recipients transplanted during February 2016 and June 2018 were analyzed. Different pre-transplant prognostic factors were identified by univariate and multivariate analyses. PVTT status was identified following Vp classification (Vp1-Vp4).
RESULTS
RESULTS
Three-year recurrence-free survival and overall survival rates were 40% and 65.4% in Vp2-Vp3 PVTT patients, 21.4% and 30.6% in Vp4 PVTT patients (P < 0.05). Total tumor diameter >8 cm, pre-transplant AFP level >1000 ng/mL and intrahepatic tumor maximal standard uptake value (SUVmax-tumor >5) were independent risk factors for HCC recurrence and overall survival after LT in Vp2-3 PVTT patients. Low risk patients were defined as total tumor diameter ≤8 cm; or if total tumor diameter more than 8 cm, with both pre-transplant AFP level less than 1000 ng/mL and intrahepatic tumor SUVmax less than 5, simultaneously. Twenty-two Vp2-3 PVTT HCC patients (46.8%) were identified as low risk patients, and their 3-year recurrence-free and overall survival rates were 67.6% and 95.2%, respectively.
CONCLUSIONS
CONCLUSIONS
Patients with segmental or lobar PVTT and biologically favorable tumors defined by AFP and
Identifiants
pubmed: 32303439
pii: S1499-3872(20)30070-9
doi: 10.1016/j.hbpd.2020.03.009
pii:
doi:
Substances chimiques
Radiopharmaceuticals
0
alpha-Fetoproteins
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-234Informations de copyright
Copyright © 2020 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.